Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795562 | 1.00 | MAPT (0.73) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL1404905 | 1.00 | MAPT (0.73) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL4185541 | 0.86 | MAPT (0.77) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL4185536 | 0.86 | MAPT (0.77) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL9622469 | 0.85 | MAPT (0.66) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL8297337 | 0.85 | MAPT (0.66) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL9622468 | 0.85 | MAPT (0.66) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL9622497 | 0.85 | MAPT (0.66) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL42323 | 0.84 | MAPT (1.00) | MAPTMAOBALDH1A1RAB9AATM | |
| SCHEMBL10673342 | 0.84 | MAPT (1.00) | MAPTMAOBALDH1A1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150584-A2 | 3,4-DIHYDROQUINAZOLINE DERIVATIVE AND COMPLEX PREPARATION CONTAINING SAME | University-Industry Cooperation Group of Kyung Hee University (KR) | 2017-04-05 | — | — | EP | disclosed |
| EP-2788359-B1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RES TRIANGLE INST (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9399701-B2 | Polymer compositions and methods | NOVOMER, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9150582-B2 | Composition and method for neuropeptide S receptor (NPSR) antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150582-B2 | Composition and method for neuropeptide S receptor (NPSR) antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2015-02-26 | — | — | US | disclosed |
| US-8003710-B2 | Production of ophthalmic devices based on photo-induced step growth polymerization | NOVARTIS AG (CH) | 2011-08-23 | — | — | US | disclosed |
| EP-2079747-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LTD (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2079747-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | Pfizer Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080143958-A1 | Production of ophthalmic devices based on photo-induced step growth polymerization | ALCON INC. (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| US-5166204-A | ISOINDOLE DERIVATIVES AND SALTS THEREOF AND ANTITUMOR AGENT COMPRISING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057268-A1 | COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS | NPSR1, TACR1, NPFFR1 | MAPT 1937/4885MAOB 511/4885ALDH1A1 3727/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | MAPT 1735/4885MAOB 177/4885ALDH1A1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.